Cancer News |

Rubraca™ Is Granted Accelerated Approval for Advanced Ovarian Cancer (12/20/2016)

The U.S. Food and Drug Administration (FDA) has granted accelerated approval to Rubraca™ (rucaparib) for the treatment of women with advanced ovarian cancer who have been treated with two or more chemotherapies and whose tumors have a BRCA gene mutation. Each year in the U.S. roughly 22,000 women are diagnosed with ovarian cancer and more … Continue reading "Rubraca™ Is Granted Accelerated Approval for Advanced Ovarian Cancer"

Lynparza™ Clinical Trial Demonstrates Survival Benefit in Relapsed Ovarian Cancer (11/09/2016)

AstraZeneca has announced positive results from the Phase III SOLO-2 trial designed to determine the efficacy of LynparzaTM (olaparib) oral therapy for the maintenance treatment of platinum-sensitive relapsed, BRCA-mutated ovarian cancer.1 Results from the trial demonstrate a clinically-meaningful improvement in survival free of cancer progression. Importantly, the median time to cancer progression for Lynparza-treated patients … Continue reading "Lynparza™ Clinical Trial Demonstrates Survival Benefit in Relapsed Ovarian Cancer"

Update on PARP Inhibitors for Ovarian Cancer with BRCA Mutations (10/31/2016)

Each year in the United States, roughly 22,000 women are diagnosed with ovarian cancer and more than 15,000 die of the disease. Treatment for ovarian cancer commonly involves surgery and/or chemotherapy. Researchers continue to study new approaches for improving the outcomes of all women affected by ovarian cancer but progress has been slow. The PARP … Continue reading "Update on PARP Inhibitors for Ovarian Cancer with BRCA Mutations"

Tesaro Provides Real Benefit to Ovarian Cancer Patients (10/20/2016)

Patients with platinum-sensitive recurrent ovarian cancer showed significantly improved cancer-free survival with Tesaro (niraparib) in the first clinical trial directly comparing a poly(ADP)-ribose polymerase (PARP) inhibitor with chemotherapy. Tesaro improved cancer-free survival by 73% in patients with a BRCA mutation and by 55% in those without such mutations. The new data were presented at the … Continue reading "Tesaro Provides Real Benefit to Ovarian Cancer Patients"

FDA Accepts Priority Review of Rucaparib For The Treatment Of Advanced Mutant BRCA Ovarian Cancer (09/06/2016)

The U.S. Food and Drug Administration (FDA) has accepted a New Drug Application (NDA) for accelerated approval of rucaparib and granted priority review status to the application for the treatment of advanced ovarian cancer in patients with deleterious BRCA-mutated cancers. Rucaparib was granted Breakthrough Therapy Designation by the FDA in April 2015. About Ovarian Cancer … Continue reading "FDA Accepts Priority Review of Rucaparib For The Treatment Of Advanced Mutant BRCA Ovarian Cancer"

SGO, ASCO Issue New Guidelines for Ovarian Cancer Treatment (08/22/2016)

A new joint clinical practice guideline from the American Society of Clinical Oncology (ASCO) and the Society of Gynecologic Oncology (SGO) states that neoadjuvant chemotherapy (NACT) is the optimal first-line treatment for some women who have newly diagnosed advanced ovarian cancer. While the standard of care in this setting is primary cytoreductive surgery (PCS) followed … Continue reading "SGO, ASCO Issue New Guidelines for Ovarian Cancer Treatment"